[go: up one dir, main page]

MX2021000387A - Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137. - Google Patents

Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.

Info

Publication number
MX2021000387A
MX2021000387A MX2021000387A MX2021000387A MX2021000387A MX 2021000387 A MX2021000387 A MX 2021000387A MX 2021000387 A MX2021000387 A MX 2021000387A MX 2021000387 A MX2021000387 A MX 2021000387A MX 2021000387 A MX2021000387 A MX 2021000387A
Authority
MX
Mexico
Prior art keywords
binding
antigne
specific binding
fragments
binding fragments
Prior art date
Application number
MX2021000387A
Other languages
English (en)
Inventor
Mihriban Tuna
Matthew Lakins
Jose Munoz-Olaya
Sarka Pechouckova
Original Assignee
F Star Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Therapeutics Ltd filed Critical F Star Therapeutics Ltd
Publication of MX2021000387A publication Critical patent/MX2021000387A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a miembros de unión específicos que se unen a CD137. Los miembros de unión específicos comprenden un sitio de unión al antígeno CD137 ubicado en un dominio constante del miembro de unión específico y encuentran aplicación en el tratamiento del cáncer y enfermedades infecciosas, por ejemplo.
MX2021000387A 2018-07-12 2019-07-12 Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137. MX2021000387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1811408.2A GB201811408D0 (en) 2018-07-12 2018-07-12 CD137 Binding Molecules
PCT/EP2019/068803 WO2020011972A1 (en) 2018-07-12 2019-07-12 Fc binding fragments comprising cd137 antigne binding side

Publications (1)

Publication Number Publication Date
MX2021000387A true MX2021000387A (es) 2021-05-27

Family

ID=63273199

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000387A MX2021000387A (es) 2018-07-12 2019-07-12 Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.

Country Status (14)

Country Link
US (2) US12103976B2 (es)
EP (1) EP3820514A1 (es)
JP (2) JP7410115B2 (es)
KR (1) KR20210030406A (es)
CN (2) CN119264257A (es)
AU (1) AU2019303032A1 (es)
BR (1) BR112021000397A2 (es)
CA (1) CA3105994A1 (es)
GB (1) GB201811408D0 (es)
IL (1) IL280005A (es)
MX (1) MX2021000387A (es)
SG (1) SG11202013107QA (es)
TW (1) TW202019475A (es)
WO (1) WO2020011972A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
AU2018387741A1 (en) 2017-12-19 2020-07-23 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
CA3098374A1 (en) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
TWI847989B (zh) 2018-07-12 2024-07-11 英商Ｆ—星治療有限公司 結合cd137及ox40的抗體分子
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
JP7504992B2 (ja) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ，インク． Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (de) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
JPS531908B2 (es) 1973-11-12 1978-01-23
JPS5746634B2 (es) 1974-05-10 1982-10-04
JPS5146628A (ja) 1974-10-17 1976-04-21 Nippon Denso Co Teikoirisupaakupuragu
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US6222012B1 (en) 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
WO1994005304A1 (en) 1992-08-31 1994-03-17 Ludwig Institute For Cancer Research Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
DE69524264T2 (de) 1994-03-01 2002-07-18 Ludwig Institute For Cancer Research, New York Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
AU760120B2 (en) 1997-12-01 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
DE19818214A1 (de) 1998-04-24 1999-10-28 Bosch Gmbh Robert Zündkerze für eine Brennkraftmaschine
EP2011801A1 (en) 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
JP4578025B2 (ja) 2001-07-06 2010-11-10 日本特殊陶業株式会社 スパークプラグ
CN1729203B (zh) 2002-10-17 2014-02-19 根马布股份公司 抗cd20的人单克隆抗体
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
DK1772465T3 (da) 2005-01-05 2009-05-25 F Star Biotech Forsch & Entw Syntetiske immunoglobulindomæner med modificerede bindingsegenskaber i områder af molekylet, der ikke er komplementaritetsbestemmende regioner
EP1851244A4 (en) 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
ES2386367T3 (es) 2005-03-10 2012-08-17 Morphotek, Inc. Anticuerpos anti-mesotelina
ME02260B (me) 2005-07-01 2016-02-29 Medarex Inc Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
CN101952319B (zh) 2007-11-26 2015-04-15 拜耳知识产权有限责任公司 抗-间皮素抗体及其用途
DK2242771T3 (da) 2007-12-14 2013-08-26 Pfizer Bindingsmolekyler til den humane ox40-receptor
MX2010011057A (es) 2008-04-11 2010-11-12 Trubion Pharmaceuticals Inc Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo.
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
NZ620326A (en) 2008-11-13 2015-07-31 Emergent Product Dev Seattle Cd37 immunotherapeutic combination therapies and uses thereof
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
AU2010230063B2 (en) 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
KR101527297B1 (ko) 2010-09-09 2015-06-26 화이자 인코포레이티드 4-1ｂｂ 결합 분자
TWI589589B (zh) 2010-12-20 2017-07-01 建南德克公司 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
KR102163408B1 (ko) 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP5276742B1 (ja) 2012-08-09 2013-08-28 日本特殊陶業株式会社 点火プラグ
ES2666131T3 (es) 2012-09-27 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral
WO2014089113A1 (en) 2012-12-03 2014-06-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
EP3424952A1 (en) 2013-03-15 2019-01-09 Amgen, Inc Heterodimeric bispecific antibodies
HUE049957T2 (hu) 2013-03-15 2020-11-30 Glaxosmithkline Ip Dev Ltd Lag-3 elleni kötõfehérjék
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
JP5902757B2 (ja) 2014-06-24 2016-04-13 日本特殊陶業株式会社 スパークプラグ
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US9407069B2 (en) 2014-08-10 2016-08-02 Federal-Mogul Ignition Company Spark plug with improved seal
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
US10233251B2 (en) 2015-02-22 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
TW201642897A (zh) 2015-04-08 2016-12-16 Ｆ 星生物科技有限公司 Ｈｅｒ２結合劑治療
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6025921B1 (ja) 2015-06-22 2016-11-16 日本特殊陶業株式会社 スパークプラグ
WO2017009456A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
EP3325009A4 (en) 2015-07-22 2018-12-05 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
PE20181151A1 (es) 2015-07-30 2018-07-17 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CA2994631A1 (en) 2015-08-07 2017-02-16 Pieris Pharmaceuticals Gmbh Novel fusion polypeptide specific for lag-3 and pd-1
EP3354661B1 (en) 2015-09-22 2020-06-03 Dingfu Biotarget Co., Ltd. Fully human antibody against human cd137 and use thereof
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
AU2016355570B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
US10501551B2 (en) 2016-01-11 2019-12-10 Inhibrx, Inc. Multivalent and multispecific 41BB-binding fusion proteins
JP6365802B2 (ja) 2016-03-18 2018-08-01 大日本印刷株式会社 中間転写媒体と熱転写シートとの組合せ、及び印画物の形成方法
ES2910365T3 (es) 2016-04-22 2022-05-12 Alligator Bioscience Ab Nuevos polipéptidos biespecíficos contra CD137
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
SG11201810591VA (en) 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
US20190106494A1 (en) 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
MX2018016320A (es) 2016-06-20 2019-05-30 F Star Delta Ltd Moleculas de union que se unen a (pd-l1) y (lag-3).
CN107523546A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的nk细胞及其用途
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US11746152B2 (en) 2016-07-20 2023-09-05 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
BR112019018759A2 (pt) 2017-05-30 2020-05-05 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
AU2018387741A1 (en) 2017-12-19 2020-07-23 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
TWI847989B (zh) 2018-07-12 2024-07-11 英商Ｆ—星治療有限公司 結合cd137及ox40的抗體分子
TWI861005B (zh) 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
WO2020229626A1 (en) 2019-05-14 2020-11-19 F-Star Delta Limited Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Also Published As

Publication number Publication date
JP7410115B2 (ja) 2024-01-09
TW202019475A (zh) 2020-06-01
BR112021000397A2 (pt) 2021-04-06
US20220119539A9 (en) 2022-04-21
AU2019303032A1 (en) 2021-03-04
WO2020011972A9 (en) 2020-02-20
US12103976B2 (en) 2024-10-01
IL280005A (en) 2021-03-01
CA3105994A1 (en) 2020-01-16
CN112739377B (zh) 2024-11-01
GB201811408D0 (en) 2018-08-29
JP7690552B2 (ja) 2025-06-10
JP2021524270A (ja) 2021-09-13
EP3820514A1 (en) 2021-05-19
SG11202013107QA (en) 2021-01-28
KR20210030406A (ko) 2021-03-17
WO2020011972A1 (en) 2020-01-16
US20210277134A1 (en) 2021-09-09
JP2024019419A (ja) 2024-02-09
CN112739377A (zh) 2021-04-30
US20250084176A1 (en) 2025-03-13
CN119264257A (zh) 2025-01-07

Similar Documents

Publication Publication Date Title
MX2021000387A (es) Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137.
MX2021002969A (es) Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1.
EP4417263A3 (en) Cd3 binding antibodies
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
MX2021003436A (es) Anticuerpos humanos para pd-1.
MX2021000399A (es) Moleculas de anticuerpo que se unen a cd137 y ox40.
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
PH12020552229A1 (en) Il-11ra antibodies
MX2022002504A (es) Anticuerpos para cd40.
MX2018016344A (es) Miembros de union lag-3.
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
GEP20207174B (en) Ctla4 binders
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
AU2015347015A8 (en) Antibody drug conjugates
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
AU2019303080B2 (en) Fc binding fragments comprising an OX40 antigen-binding site
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations